Page last updated: 2024-08-23

epirubicin and Adenocarcinoma, Clear Cell

epirubicin has been researched along with Adenocarcinoma, Clear Cell in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (16.67)	18.2507
2000's	3 (50.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abraham, J; Basu, B; Brenton, J; Earl, H; Freeman, S; Gounaris, I; Hatcher, H; Hosking, K; Iddawela, M; Jimenez-Linan, M; Moyle, P; Parkinson, C; Sayal, K	1
Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M	1
Aravantinos, G; Dimopoulos, MA; Economopoulos, T; Efstathiou, H; Farmakis, D; Fountzilas, G; Kalofonos, C; Pavlidis, N; Pectasides, D; Skarlos, D	1
Colombo, N; Fossati, R; Fruscio, R; Garbi, A; Ieda', N; Lissoni, AA; Mangioni, C; Torri, V	1
Aravantinos, G; Bafaloukos, D; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Papadimitriou, CA	1
Nishida, T; Sugiyama, T; Yakushiji, M	1

Trials

4 trial(s) available for epirubicin and Adenocarcinoma, Clear Cell

Article	Year
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:6 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate	2015
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. British journal of cancer, 2008, Feb-26, Volume: 98, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Epirubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors	2008
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecologic oncology, 2008, Volume: 110, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Endometrial Neoplasms; Epirubicin; Female; Greece; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence	2008
Cisplatin, epirubicin, and ifosfamide versus cisplatin, epirubicin, and cyclophosphamide in clear cell carcinoma of the ovary. Gynecologic oncology, 1997, Volume: 67, Issue:2 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Ifosfamide; Ovarian Neoplasms	1997

Other Studies

2 other study(ies) available for epirubicin and Adenocarcinoma, Clear Cell

Article	Year
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy? European journal of gynaecological oncology, 2016, Volume: 37, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies	2016
Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecologic oncology, 2006, Volume: 102, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate	2006

Article

Year

Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?

European journal of gynaecological oncology, 2016, Volume: 37, Issue:2

Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies

2016

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Gynecologic oncology, 2006, Volume: 102, Issue:2

Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate

2006